Intelligence / Healthtech / De Novo Grants / Randox Laboratories, Ltd.
Approvalsnovel device granted (FDA De Novo)22 May 2025
Randox Laboratories, Ltd.
22 May 2025: Novel device granted (FDA De Novo) · ConcizuTrace ELISA. Recorded in the openFDA device 510(k) (De Novo decisions).
- Granted
- 22 May 2025
- Device
- ConcizuTrace ELISA
- Specialty
- Hematology
- Product Code
- SES
- Country
- United Kingdom
- Location
- Crumlin, United Kingdom
- Submitted
- 2024-07-01
- Reference
- DEN240035
What this signal means
A De Novo grant creates a new device category: reimbursement coding, distribution, clinical evidence, manufacturing scale-up and sales hires follow.
- 2 added in the 30 days to 19 Nov 2026.
- Neurology leads (10); 29% went to makers outside the US.
Reach them with AOS
Find the decision makers at Randox Laboratories, Ltd.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.
More in Hematology
De Novo Grants
19 SeptCytocell Limitednovel device granted (FDA De Novo) · KMT2A Breakapart FISH Probe Kit PDx (CDA-LPH013)Approvals5 DecVentana Medical Systems, Inc.novel device granted (FDA De Novo) · VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail (08507023001)Approvals
Source: openFDA device 510(k) (De Novo decisions), data to 19 Nov 2026. Every De Novo classification FDA granted in the last 24 months: a novel device with no legally marketed predicate, which creates a new device type and product code. AOS shows what the public record says; it does not verify or endorse the company.